查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601706

胜肽治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按應用、類型、製造商類型、給藥途徑、合成技術、地區和競爭細分，2019-2029F

Peptide Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Type, By Type of Manufacturers, By Route of Administration, By Synthesis Technology, By Region, and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球胜肽治療市場估值為427.8 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為6.75%。 ，全球胜肽治療市場一直在穩定成長。肽療法是短鏈氨基酸，已顯示出治療多種疾病的潛力，包括癌症、代謝紊亂、心血管疾病和傳染病。

市場概況
預測期 2025-2029
2023 年市場規模 427.8億美元
2029 年市場規模 630.3億美元
2024-2029 年複合年成長率 6.75%
成長最快的細分市場 代謝紊亂
最大的市場 北美洲

主要市場促進因素

研究與科技的進步

慢性病盛行率上升

個人化醫療和標靶治療

主要市場挑戰

胜肽穩定性和遞送

生產成本

來自其他方式的競爭

主要市場趨勢

增強的胜肽穩定性和遞送系統

聯合療法和多模式方法

擴大治療應用

細分市場洞察

應用見解

類型洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球胜肽治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依應用分類（癌症、代謝失調、心血管疾病、呼吸系統疾病、胃腸道疾病、傳染病、疼痛、皮膚疾病、神經系統疾病、腎臟疾病等）
    • 按類型（通用、創新）
    • 依製造商類型（內部、外包）
    • 依給藥途徑（腸胃外途徑、口服途徑、肺部、黏膜、其他）
    • 依合成技術分類（固相胜肽合成（SPPS）、液相胜肽合成（LPPS）、混合技術）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美胜肽治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按申請
    • 按類型
    • 按製造商類型
    • 依給藥途徑
    • 透過合成技術
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲胜肽治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按申請
    • 按類型
    • 按製造商類型
    • 依給藥途徑
    • 透過合成技術
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區胜肽治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按申請
    • 按類型
    • 按製造商類型
    • 依給藥途徑
    • 透過合成技術
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲胜肽治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按申請
    • 按類型
    • 按製造商類型
    • 依給藥途徑
    • 透過合成技術
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲胜肽治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按申請
    • 按類型
    • 按製造商類型
    • 依給藥途徑
    • 透過合成技術
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Eli Lilly and Co.
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Co Ltd.
  • AstraZeneca Pharmaceuticals LP
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Novo Nordisk A/S

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 24050

Global Peptide Therapeutics Market was valued at USD 42.78 billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.75% through 2029. The global peptide therapeutics market has been experiencing steady growth due to the increasing demand for targeted and personalized treatments in various medical fields. Peptide therapeutics are short chains of amino acids that have shown potential in treating a wide range of diseases, including cancer, metabolic disorders, cardiovascular diseases, and infectious diseases.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 42.78 Billion
Market Size 2029USD 63.03 Billion
CAGR 2024-20296.75%
Fastest Growing SegmentMetabolic Disorders
Largest MarketNorth America

Key Market Drivers

Advancements in Research & Technology

The world of healthcare is undergoing a remarkable transformation, driven by rapid advancements in research and technology. One sector that stands at the forefront of this revolution is the global peptide therapeutics market. Peptide therapeutics, short chains of amino acids with potent biological activity, have emerged as a beacon of hope for addressing a wide spectrum of diseases. The symbiotic relationship between research and technology has been instrumental in propelling the growth of this market, opening up unprecedented opportunities for innovation and patient care. Peptide therapeutics are distinct from traditional drugs due to their precision targeting and potential for reduced side effects. These compounds can be engineered to interact with specific receptors, enzymes, or other molecular targets involved in disease processes. However, their journey from laboratory discovery to effective clinical applications is dependent on cutting-edge research and technology. A pivotal driver of growth in the peptide therapeutics market is the evolution of peptide synthesis techniques. Early methods faced challenges related to scalability, complexity, and yield. However, recent breakthroughs have ushered in more efficient and cost-effective approaches. Solid-phase peptide synthesis (SPPS), for instance, revolutionized the field by enabling the stepwise assembly of peptides, facilitating the creation of longer and more intricate sequences with greater precision. In the quest for enhancing peptide stability and therapeutic efficacy, researchers have delved into modification strategies. Conjugation with stabilizing moieties, incorporation of non-natural amino acids, and cyclization are among the methods employed to increase peptide half-life and resistance to degradation. These modifications have not only extended the therapeutic window but have also enabled the targeting of intracellular pathways that were previously deemed challenging. Advancements in computational tools and bioinformatics have transformed the landscape of peptide drug discovery. Computer simulations and modeling can predict the interactions between peptides and target proteins, accelerating the design and optimization of potential therapeutic candidates. This synergy between technology and research has significantly shortened the timeline from target identification to preclinical development. The convergence of research and technology has led to the development of innovative delivery systems for peptides. Nanoparticles, liposomes, and other carriers can encapsulate peptides, ensuring their safe transport to target sites within the body. This has not only improved the pharmacokinetics of peptides but also broadened their therapeutic applications, from crossing the blood-brain barrier for neurodegenerative diseases to enhancing site-specific tumor targeting.

Rising Prevalence of Chronic Diseases

In an era characterized by rapid lifestyle changes, environmental factors, and an aging population, the global healthcare landscape is witnessing an alarming surge in chronic diseases. This escalating burden of conditions such as diabetes, cardiovascular disorders, and cancer has catalyzed the need for innovative and targeted treatment approaches. Among the emerging contenders in this landscape, peptide therapeutics have garnered substantial attention. Chronic diseases have become a global health crisis, affecting individuals of all ages, backgrounds, and geographical locations. Factors such as sedentary lifestyles, poor dietary choices, stress, and genetic predispositions have converged to create an environment conducive to the development of chronic conditions. From diabetes to cardiovascular diseases and neurodegenerative disorders, these ailments often impose a significant burden on healthcare systems and patients alike. Enter peptide therapeutics, a class of molecules with the potential to revolutionize the treatment landscape for chronic diseases. Unlike traditional pharmaceuticals, peptides offer a unique advantage in their precision targeting capabilities. These short chains of amino acids can be designed to specifically interact with biological molecules involved in disease progression. This level of specificity enables more effective interventions, minimizing collateral damage to healthy cells and tissues. One of the cornerstones of tackling chronic diseases effectively is the concept of personalized medicine. Peptide therapeutics align perfectly with this approach, allowing for the creation of treatments tailored to the individual characteristics of each patient. By targeting specific molecular pathways or biomarkers associated with a patient's condition, peptide therapies can offer enhanced efficacy while potentially reducing the risk of adverse effects. Chronic diseases often arise from intricate interactions among multiple genetic, environmental, and lifestyle factors. This complexity makes finding effective treatments a challenging endeavor. Peptide therapeutics, however, have the potential to address these multi-faceted disease mechanisms. Through targeted interactions with key proteins and receptors, peptides can modulate complex pathways involved in disease progression, offering a comprehensive approach to treatment. The versatility of peptide therapeutics has led to their application across a wide spectrum of chronic diseases. From diabetes to autoimmune disorders and cardiovascular diseases, these molecules can be engineered to tackle the specific challenges posed by each condition. For instance, peptides can mimic the action of natural hormones, regulate immune responses, or disrupt aberrant signaling pathways. As a result, they are emerging as a promising tool in managing chronic diseases that previously lacked effective treatment options.

Personalized Medicine and Targeted Therapies

The evolution of healthcare has ushered in a new era of personalized medicine, centered around the concept of tailoring treatments to individual patients based on their unique characteristics. In this transformative landscape, targeted therapies have emerged as a beacon of hope, offering precise interventions with minimal side effects. At the heart of this paradigm shift lies the global peptide therapeutics market, which is rapidly gaining traction due to its ability to align seamlessly with the principles of personalized medicine and targeted therapies. Traditional approaches to medicine often take a one-size-fits-all approach, treating patients based on broad guidelines. However, the realization that individuals respond differently to treatments due to their genetic makeup, lifestyle, and other factors has led to a paradigm shift towards personalized medicine. This approach seeks to optimize patient outcomes by tailoring interventions to their specific needs, ultimately enhancing treatment efficacy and reducing adverse effects. At the forefront of personalized medicine are targeted therapies that address the root causes of diseases at a molecular level. Peptide therapeutics, composed of short chains of amino acids, offer a remarkable level of precision due to their customizable nature. Researchers can engineer peptides to specifically interact with disease-related molecules, be it receptors, enzymes, or other cellular components. This customization aligns perfectly with the individualized nature of personalized medicine. Peptide therapeutics have redefined the landscape of targeted therapies. By designing peptides to interact with specific biomarkers or genetic variations associated with a patient's condition, healthcare professionals can administer treatments that are uniquely suited to each individual. This approach minimizes the risk of treatment resistance and reduces unnecessary exposure to drugs that may not be effective for a particular patient. Complex diseases often involve intricate interactions among multiple molecular pathways. Peptide therapeutics excel in addressing this complexity, as they can simultaneously target multiple components of disease processes. This ability is crucial for diseases with multifaceted causes, such as cancer and autoimmune disorders. By offering a multi-pronged approach, peptides enhance the chances of success in treating complex conditions. Biomarkers play a pivotal role in guiding personalized treatment decisions. Peptide therapeutics can be designed to specifically interact with disease-related biomarkers, allowing for real-time monitoring and adjustments in treatment plans. This dynamic approach enables healthcare providers to optimize therapies based on a patient's evolving condition, leading to more effective outcomes.

Key Market Challenges

Peptide Stability & Delivery

Peptide therapeutics have emerged as a promising avenue for targeted treatments across various diseases, from cancer to metabolic disorders. Their potential to interact with specific cellular targets offers precision in therapy, reducing side effects and improving patient outcomes. However, despite these advantages, the growth of the global peptide therapeutics market is hindered by significant challenges, chief among them being peptide stability and delivery. Peptides are inherently sensitive molecules. Their susceptibility to degradation in the body, during storage, and upon administration poses a substantial hurdle to their successful application as therapeutic agents. Maintaining the structural integrity of peptides is crucial for ensuring their effectiveness in reaching and interacting with target molecules. Delivering peptides to their intended sites of action in the body is equally complex, as they often need to bypass biological barriers and obstacles to reach their targets.

Production Costs

Peptide therapeutics are composed of short chains of amino acids and can be designed to target specific disease-related molecules with remarkable precision. Their potential to address complex diseases, reduce side effects, and offer personalized treatments has garnered substantial attention. However, the intricacies of peptide synthesis, purification, and formulation contribute to elevated production costs, posing challenges for both developers and patients. The process of synthesizing peptides can be intricate and labor-intensive. Each amino acid in the peptide sequence must be added one by one, requiring multiple steps and reagents. This complexity contributes to time-consuming and resource-intensive production processes. After synthesis, peptides need to be purified to ensure their safety, efficacy, and quality. Advanced purification methods and extensive quality control measures increase production costs and resource consumption.

Competition from Other Modalities

The global peptide therapeutics market holds significant promise for targeted and personalized disease treatments. However, amidst this potential, the market faces a formidable challenge: competition from other therapeutic modalities. From established biologics to emerging gene therapies and small molecule drugs, these alternative treatment approaches can hinder the growth of the peptide therapeutics market. Biologics, including monoclonal antibodies and recombinant proteins, have been established in the market for decades. These large molecules have gained traction due to their efficacy in treating various diseases, and they often enjoy robust market share and familiarity among healthcare professionals. Small molecules are widely used therapeutic agents due to their oral bioavailability, ease of manufacturing, and established drug development pathways. They dominate many therapeutic areas, including chronic diseases, due to their pharmacological diversity and cost-effectiveness.

Key Market Trends

Enhanced Peptide Stability & Delivery Systems

Overcoming the challenge of peptide stability and delivery has been a focus of intense research. Innovations such as nanoparticle-based delivery systems, sustained-release formulations, and modifications to enhance peptide stability are making significant strides. These advancements are extending the half-life of peptides, enabling targeted delivery, and ultimately improving their therapeutic potential.

Combination Therapies & Multi-Modal Approaches

Combining different therapeutic modalities to achieve synergistic effects is gaining traction in the peptide therapeutics market. Peptides are being used as targeting agents in combination with other treatments, such as chemotherapy or gene therapies. This trend maximizes therapeutic impact while minimizing side effects and treatment resistance.

Expanding Therapeutic Applications

The versatility of peptide therapeutics is leading to an expanding range of therapeutic applications. From cancer to cardiovascular diseases, metabolic disorders to autoimmune conditions, peptides are being investigated for their potential in a wide spectrum of diseases. This trend reflects the adaptability of peptides to address diverse disease mechanisms.

Segmental Insights

Applications Insights

In 2023, the global peptide therapeutics market witnessed significant dominance from the metabolic disorders segment, closely followed by the cancer segment. The metabolic disorders category stood out with the highest revenue share, capturing a substantial portion of the market. This dominance can be attributed to the escalating prevalence of metabolic issues worldwide. Factors such as sedentary lifestyles, unhealthy dietary habits, and excessive alcohol consumption have contributed to the increased incidence of metabolic disorders. The aging population, which is particularly susceptible to metabolic ailments, presents a lucrative growth opportunity for the market. As the elderly population continues to grow, the demand for peptide therapeutics to manage metabolic disorders is expected to rise steadily, further bolstering the dominance of this segment.

In 2023, cancer emerged as the second-largest segment in the global peptide therapeutics market. The increasing incidence rates of cancer globally, coupled with the growing adoption of peptide therapies for cancer treatment, drove the expansion of this segment. There is a growing recognition of the efficacy of peptide-based drugs in targeting cancer cells with precision and minimal side effects. As a result, healthcare professionals are increasingly prescribing peptide therapies for cancer management. The demand for effective and fast-acting medications to combat cancer is expected to propel the growth of this segment in the forecast period. The dominance of the metabolic disorders segment and the significant growth of the cancer segment underscore the diverse applications and growing demand for peptide therapeutics in addressing a wide range of medical conditions. With ongoing research and development efforts aimed at expanding the therapeutic capabilities of peptides, the global peptide therapeutics market is poised for further growth and innovation in the years to come.

Type Insights

In 2023, the global peptide therapeutics market witnessed significant dominance from the generic segment, a trend that is poised to continue expanding in the years ahead. Despite the innovative category holding the highest revenue share in 2023, the generic segment emerged as a formidable force due to a myriad of factors driving its growth trajectory. The innovative category, while commanding a substantial portion of the market, faced strong competition from the generic segment. This competition was fueled by several key dynamics within the pharmaceutical landscape. Foremost among these was the increasing research and development spending by large pharmaceutical companies. These companies allocated significant resources towards the development of new peptide therapeutics, aiming to address unmet medical needs and capitalize on emerging market opportunities.

It was the generic segment that truly captured the spotlight in the global peptide therapeutics market. One of the primary catalysts for the dominance of generics was the patent expirations of branded peptide drugs. As patents for these drugs reached their expiration dates, it paved the way for generic manufacturers to enter the market with alternative, more cost-effective versions of these therapies. The growing demand for affordable treatments further bolstered the position of the generic segment. Patients and healthcare providers alike sought out generic alternatives due to their lower prices, making them increasingly attractive in a healthcare landscape characterized by rising costs. Regulatory pathways facilitating the approval of generic peptide therapeutics played a pivotal role in the segment's dominance. Regulatory agencies streamlined the approval process for generic drugs, enabling faster market entry and fostering a competitive environment among manufacturers. The intensifying competition among generic manufacturers underscored their ability to offer bioequivalent products, ensuring comparable efficacy and safety profiles to their branded counterparts.

Regional Insights

In 2023, the North America region solidified its position as the frontrunner in the global Peptide Therapeutics market, boasting the highest revenue share and leading the market with remarkable dominance. This achievement is not merely a coincidence but rather a result of various strategic factors that have propelled North America to the forefront of peptide therapeutics.

One of the primary drivers of North America's market leadership is the expansion of the biotechnology sector within the region. North America, particularly the United States, is renowned for its robust biotechnology industry, characterized by cutting-edge research, technological innovation, and a favorable regulatory environment. The region is home to numerous biotechnology companies, research institutions, and academic centers that spearhead advancements in peptide therapeutics. This thriving biotech ecosystem provides a fertile ground for the development and commercialization of novel peptide-based drugs, bolstering North America's dominance in the global market. The rising demand for cancer diagnostics and treatments has significantly contributed to North America's leadership in peptide therapeutics. As one of the leading causes of mortality worldwide, cancer represents a significant healthcare burden, driving the need for innovative therapeutic approaches. Peptide-based therapies have garnered attention for their potential efficacy and specificity in targeting cancer cells, fueling their adoption in oncology research and clinical practice across North America.

Key Market Players

  • Eli Lilly and Co.
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Co Ltd.
  • AstraZeneca Pharmaceuticals LP
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Novo Nordisk A/S

Report Scope:

In this report, the Global Peptide Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Therapeutics Market, By Application:

  • Cancer
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Respiratory Disorders
  • Gastrointestinal Disorders
  • Infectious Diseases
  • Pain
  • Dermatological Disorders
  • Neurological Disorders
  • Renal Disorders
  • Others

Peptide Therapeutics Market, By Type:

  • Generic
  • Innovative

Peptide Therapeutics Market, By Type of Manufacturers:

  • In-house
  • Outsourced

Peptide Therapeutics Market, By Route of Administration:

  • Parenteral Route
  • Oral Route
  • Pulmonary
  • Mucosal
  • Others

Peptide Therapeutics Market, By Synthesis Technology:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Peptide Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Therapeutics Market.

Available Customizations:

Global Peptide Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Cancer, Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others)
    • 5.2.2. By Type (Generic, Innovative)
    • 5.2.3. By Type of Manufacturers (In-house, Outsourced)
    • 5.2.4. By Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others)
    • 5.2.5. By Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology)
    • 5.2.6. By Region
    • 5.2.7. By Company (2023)
  • 5.3. Market Map

6. North America Peptide Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Type
    • 6.2.3. By Type of Manufacturers
    • 6.2.4. By Route of Administration
    • 6.2.5. By Synthesis Technology
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Type of Manufacturers
        • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.5. By Synthesis Technology
    • 6.3.2. Canada Peptide Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Type of Manufacturers
        • 6.3.2.2.4. By Route of Administration
        • 6.3.2.2.5. By Synthesis Technology
    • 6.3.3. Mexico Peptide Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Type of Manufacturers
        • 6.3.3.2.4. By Route of Administration
        • 6.3.3.2.5. By Synthesis Technology

7. Europe Peptide Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Type
    • 7.2.3. By Type of Manufacturers
    • 7.2.4. By Route of Administration
    • 7.2.5. By Synthesis Technology
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Peptide Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Type of Manufacturers
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Synthesis Technology
    • 7.3.2. Germany Peptide Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Type of Manufacturers
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Synthesis Technology
    • 7.3.3. United Kingdom Peptide Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Type of Manufacturers
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Synthesis Technology e
    • 7.3.4. Italy Peptide Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Type of Manufacturers
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By Synthesis Technology
    • 7.3.5. Spain Peptide Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Type of Manufacturers
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By Synthesis Technology

8. Asia-Pacific Peptide Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Type
    • 8.2.3. By Type of Manufacturers
    • 8.2.4. By Route of Administration
    • 8.2.5. By Synthesis Technology
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Peptide Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Type of Manufacturers
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Synthesis Technology
    • 8.3.2. India Peptide Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Type of Manufacturers
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Synthesis Technology
    • 8.3.3. South Korea Peptide Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Type of Manufacturers
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Synthesis Technology
    • 8.3.4. Japan Peptide Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Type of Manufacturers
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By Synthesis Technology
    • 8.3.5. Australia Peptide Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Type of Manufacturers
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By Synthesis Technology

9. South America Peptide Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Type
    • 9.2.3. By Type of Manufacturers
    • 9.2.4. By Route of Administration
    • 9.2.5. By Synthesis Technology
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Peptide Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Type of Manufacturers
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Synthesis Technology
    • 9.3.2. Argentina Peptide Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Type of Manufacturers
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Synthesis Technology
    • 9.3.3. Colombia Peptide Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Type of Manufacturers
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Synthesis Technology

10. Middle East and Africa Peptide Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Type
    • 10.2.3. By Type of Manufacturers
    • 10.2.4. By Route of Administration
    • 10.2.5. By Synthesis Technology
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Peptide Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Type of Manufacturers
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Synthesis Technology
    • 10.3.2. Saudi Arabia Peptide Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Type of Manufacturers
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Synthesis Technology
    • 10.3.3. UAE Peptide Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Type of Manufacturers
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Synthesis Technology
    • 10.3.4. Kuwait Peptide Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Application
        • 10.3.4.2.2. By Type
        • 10.3.4.2.3. By Type of Manufacturers
        • 10.3.4.2.4. By Route of Administration
        • 10.3.4.2.5. By Synthesis Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Eli Lilly and Co.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. Amgen Inc.
  • 14.4. Takeda Pharmaceutical Co Ltd.
  • 14.5. AstraZeneca Pharmaceuticals LP
  • 14.6. Teva Pharmaceutical Industries Ltd.
  • 14.7. Sanofi S.A.
  • 14.8. F Hoffmann-La Roche AG
  • 14.9. Novartis AG
  • 14.10. Novo Nordisk A/S

15. Strategic Recommendations

16. About Us & Disclaimer